Tuesday, October 13, 2026
ExploreSearch
Via News
MarketIndexes

CBOE Over 23% Down In The Last 21 Sessions

ViaNews Editorial Team

December 1, 2023

CBOE Over 23% Down In The Last 21 Sessions

(VIANEWS) - CBOE (VIX) has been up by 23.71% for the last 21 sessions. At 01:09 EST on Friday, 1 December, CBOE (VIX) is $12.87.

Concerning CBOE's yearly highs and lows, it's 0% down from its 52-week low and 63.28% down from its 52-week high.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CBOE's is considered to be oversold (<=20).

News about

  • According to FXStreet on Tuesday, 28 November, "As per an agreement with the NASDAQ exchange, Mullen needs to raise its share price above $1 by late January of next year. "

More news about CBOE (VIX).

Categories

MarketIndexes

Tags

IndexWorld IndicesVIXIndicesCBOEPrice DownINDICES Price DownIndex Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com